Aradigm Corporation

Equities

ARDMQ

US0385054004

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		+6.73%	-25.81%

2020	Aradigm Corporation Went Out of Business	CI
2020	Modified Combined Liquidation Plan and Discosure Statement Approved for Aradigm Corporation	CI

Aradigm Corporation Announces Tamar Howson Will Not Stand for Re-Election at the Annual Meeting

March 28, 2013 at 03:57 pm

Aradigm Corporation announced that on March 22, 2013, Ms. Tamar Howson informed the company and the Board of Directors that she will not stand for re-election at the company's Annual Meeting of Shareholders on May 22, 2013.

Latest news about Aradigm Corporation

Aradigm Corporation Went Out of Business	29/06/20	CI
Modified Combined Liquidation Plan and Discosure Statement Approved for Aradigm Corporation	12/06/20	CI
Revised Disclosure Statement Conditionally Approved for Aradigm Corporation	27/04/20	CI
Combined Liquidation Plan and Disclosure Statement Filed by Aradigm Corporation	08/04/20	CI
Grifols, S.A. completed the acquisition of Assets and Intellectual Property of Lipoquin, Free Ciprofloxacin, Apulmiq from Aradigm Corporation (OTCPK:ARDM.Q).	30/03/20	CI
Motion for Asset Sale Approved for Aradigm Corporation	30/03/20	CI
Bidding Procedure Approved for Aradigm Corporation	09/03/20	CI
Motion for Asset Sale Filed by Aradigm Corporation	21/02/20	CI
Grifols, S.A. entered into an asset purchase agreement to acquire Assets and Intellectual Property of Lipoquin, Free Ciprofloxacin, Apulmiq from Aradigm Corporation (OTCPK:ARDM.Q) for $6.3 million.	20/02/20	CI
Second Motion for Exclusivity Period Extension Approved For Aradigm Corporation	06/11/19	CI
Aradigm Corporation Announces Withdrawal of European Marketing Authorization Application for Linhaliq	30/10/19	CI
Aradigm Corporation Receives Feedback Following an Oral Explanation with the European Medicines Agency	21/10/19	CI
Motion for Exclusivity Period Extension Approved For Aradigm Corporation	19/07/19	CI
First Motion for Exclusivity Period Extension Filed by Aradigm Corporation	14/06/19	CI
DIP Financing Approved for Aradigm Corporation	06/06/19	CI
Aradigm Announces Receipt of Final FDA Minutes for the Type B Meeting on January 25, 2019	22/02/19	CI
Aradigm Corporation will Change its Ticker to ARDM.Q from ARDM	20/02/19	CI
Aradigm Corporation Announces Management Changes	19/02/19	CI
Aradigm Corporation Filed for Bankruptcy	15/02/19	CI
Aradigm Intends To Sell Assets	15/02/19	CI
Aradigm Corporation Announces Detailed Third Party Evaluation Results for Apulmiq/Linhaliq	16/01/19	CI
Aradigm Corporation(OTCPK:ARDM) dropped from S&P TMI Index	16/01/19	CI
Aradigm Corporation(OTCPK:ARDM.Q) dropped from NASDAQ Composite Index	15/01/19	CI
Aradigm Corporation announced that it has received $4 million in funding from Grifols Worldwide Operations Ltd.	01/01/19	CI
Aradigm Announces Results of Third Party Verification for Apulmiq	20/12/18	CI

Chart Aradigm Corporation

Duration

Period

More charts

Company Profile

Aradigm Corp is a United States-based company. The Company is an emerging specialty pharmaceutical company focused on the development and commercialization of drugs for the prevention and treatment of severe respiratory diseases. Its inhaled ciprofloxacin formulations are also product candidates for treatment of patients with cystic fibrosis and non-tuberculous mycobacteria, and for the prevention and treatment of high threat and bioterrorism infections, such as inhaled tularemia, pneumonic plague, melioidosis, Q fever and inhaled anthrax.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ARADIGM CORPORATION	-25.81%	702K
MODERNA, INC.	+46.19%	55.7B
IQVIA HOLDINGS INC.	-6.14%	39.57B
LONZA GROUP AG	+40.01%	39.91B
CELLTRION, INC.	-6.65%	28.16B
ICON PUBLIC LIMITED COMPANY	+12.33%	26.3B
ALNYLAM PHARMACEUTICALS, INC.	-21.78%	18.94B
BIO-TECHNE CORPORATION	-0.35%	12.12B
UNITED THERAPEUTICS CORPORATION	+24.18%	12.12B
MEDPACE HOLDINGS, INC.	+28.38%	12.17B

Other Biotechnology & Medical Research